AbbVie’s big-selling Humira will face competition from at least three biosimilars in Europe in around a year’s time, after the European Commission approved a biosimilar from Boehringer Inge
IQVIA’s Murray Aitken examines the potential for savings from a new wave of oncology biosimilars – but says payers have to invest in education and incentives to maximise uptake.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
